Restoration of T and B Cell Differentiation after RAG1 Gene Transfer in Human RAG1 Defective Hematopoietic Stem Cells

Nataël Sorel,Francisco Díaz-Pascual,Boris Bessot,Hanem Sadek,Chloé Mollet,Myriam Chouteau,Marco Zahn,Irene Gil-Farina,Parisa Tajer,Marja van Eggermond,Dagmar Berghuis,Arjan C Lankester,Isabelle André,Richard Gabriel,Marina Cavazzana,Kasrin Pike-Overzet,Frank J T Staal,Chantal Lagresle-Peyrou

DOI: https://doi.org/10.3390/biomedicines12071495

IF: 4.757

2024-07-05

Biomedicines

Abstract:Recombinase-activating gene (RAG)-deficient SCID patients lack B and T lymphocytes due to the inability to rearrange immunoglobulin and T cell receptor genes. The two RAG genes act as a required dimer to initiate gene recombination. Gene therapy is a valid treatment alternative for RAG-SCID patients who lack a suitable bone marrow donor, but developing such therapy for RAG1/2 has proven challenging. Using a clinically approved lentiviral vector with a codon-optimized RAG1 gene, we report here preclinical studies using CD34+ cells from four RAG1-SCID patients. We used in vitro T cell developmental assays and in vivo assays in xenografted NSG mice. The RAG1-SCID patient CD34+ cells transduced with the RAG1 vector and transplanted into NSG mice led to restored human B and T cell development. Together with favorable safety data on integration sites, these results substantiate an ongoing phase I/II clinical trial for RAG1-SCID.